Inhibrx (NASDAQ:INBX) Receives “Market Perform” Rating from JMP Securities

Inhibrx (NASDAQ:INBX)‘s stock had its “market perform” rating reaffirmed by JMP Securities in a research report issued on Wednesday,Benzinga reports.

Inhibrx Trading Down 0.3 %

INBX stock traded down $0.04 during mid-day trading on Wednesday, reaching $14.15. 2,038 shares of the stock traded hands, compared to its average volume of 77,572. Inhibrx has a one year low of $10.80 and a one year high of $18.95. The business has a 50-day moving average price of $14.68 and a two-hundred day moving average price of $14.67.

Insiders Place Their Bets

In related news, Director Jon Faiz Kayyem acquired 69,686 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average cost of $14.23 per share, with a total value of $991,631.78. Following the transaction, the director now directly owns 51,093 shares of the company’s stock, valued at $727,053.39. This trade represents a -374.80 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Hedge Funds Weigh In On Inhibrx

A hedge fund recently bought a new stake in Inhibrx stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 22,584 shares of the company’s stock, valued at approximately $348,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management owned 0.16% of Inhibrx at the end of the most recent quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.